246 related articles for article (PubMed ID: 35968339)
1. Multiple myeloma with t(11;14): unique biology and evolving landscape.
Bal S; Kumar SK; Fonseca R; Gay F; Hungria VT; Dogan A; Costa LJ
Am J Cancer Res; 2022; 12(7):2950-2965. PubMed ID: 35968339
[TBL] [Abstract][Full Text] [Related]
2. Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.
Diamantidis MD; Papadaki S; Hatjiharissi E
Front Oncol; 2022; 12():934008. PubMed ID: 35982976
[TBL] [Abstract][Full Text] [Related]
3. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression in patients with multiple myeloma.
Troussard X; Avet-Loiseau H; Macro M; Mellerin MP; Malet M; Roussel M; Sola B
Hematol J; 2000; 1(3):181-5. PubMed ID: 11920187
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).
Kobayashi H; Saito H; Kitano K; Kiyosawa K; Gaun S; Aoki K; Narita A; Watanabe M; Uchimaru K; Motokura T
Acta Haematol; 1995; 94(4):199-203. PubMed ID: 8610478
[TBL] [Abstract][Full Text] [Related]
9. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.
Yufu Y; Goto T; Choi I; Uike N; Kozuru M; Ohshima K; Taniguchi T; Motokura T; Yatabe Y; Nakamura S
Cancer; 1999 Apr; 85(8):1750-7. PubMed ID: 10223569
[TBL] [Abstract][Full Text] [Related]
10. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
11. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Janssen JW; Vaandrager JW; Heuser T; Jauch A; Kluin PM; Geelen E; Bergsagel PL; Kuehl WM; Drexler HG; Otsuki T; Bartram CR; Schuuring E
Blood; 2000 Apr; 95(8):2691-8. PubMed ID: 10753852
[TBL] [Abstract][Full Text] [Related]
12. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
[TBL] [Abstract][Full Text] [Related]
13. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1.
Yata K; Sadahira Y; Otsuki T; Sakaguchi H; Isozaki Y; Uno M; Kurebayashi J; Fujii T; Eda S; Ueki A; Yawata Y; Yamada O; Sugihara T
Br J Haematol; 2001 Sep; 114(3):591-9. PubMed ID: 11552984
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
17. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
18. Biology and treatment of multiple myeloma.
Niesvizky R; Siegel D; Michaeli J
Blood Rev; 1993 Mar; 7(1):24-33. PubMed ID: 8467229
[TBL] [Abstract][Full Text] [Related]
19. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma.
Kleber M; Ntanasis-Stathopoulos I; Terpos E
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136374
[TBL] [Abstract][Full Text] [Related]
20. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]